Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Depreciation & Amortization (CF) (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Depreciation & Amortization (CF) for 12 consecutive years, with $44000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) rose 4.76% year-over-year to $44000.0, compared with a TTM value of $198000.0 through Sep 2025, up 3.66%, and an annual FY2024 reading of $200000.0, changed 0.0% over the prior year.
  • Depreciation & Amortization (CF) was $44000.0 for Q3 2025 at Lisata Therapeutics, roughly flat from $44000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $67000.0 in Q4 2024 and bottomed at $42000.0 in Q3 2024.
  • Average Depreciation & Amortization (CF) over 3 years is $48272.7, with a median of $46000.0 recorded in 2024.
  • Peak annual rise in Depreciation & Amortization (CF) hit 15.52% in 2024, while the deepest fall reached 10.64% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $58000.0 in 2023, then rose by 15.52% to $67000.0 in 2024, then tumbled by 34.33% to $44000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for LSTA at $44000.0 in Q3 2025, $44000.0 in Q2 2025, and $43000.0 in Q1 2025.